X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Aurobindo Pharma with VENUS REMEDIES - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

AUROBINDO PHARMA vs VENUS REMEDIES - Comparison Results

AUROBINDO PHARMA    Change

Aurobindo Pharma is one of India's top 5 pharma companies in terms of turnover, and has presence in the generic and Active Pharmaceutical Ingredients (API) segments. The company's robust product portfolio is spread across 6 product areas, including a... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    AUROBINDO PHARMA VENUS REMEDIES AUROBINDO PHARMA/
VENUS REMEDIES
 
P/E (TTM) x 19.4 -3.8 - View Chart
P/BV x 3.6 0.1 2,548.4% View Chart
Dividend Yield % 0.3 0.0 -  

Financials

 AUROBINDO PHARMA   VENUS REMEDIES
EQUITY SHARE DATA
    AUROBINDO PHARMA
Mar-18
VENUS REMEDIES
Mar-18
AUROBINDO PHARMA/
VENUS REMEDIES
5-Yr Chart
Click to enlarge
High Rs809126 642.6%   
Low Rs50461 824.9%   
Sales per share (Unadj.) Rs281.1301.8 93.1%  
Earnings per share (Unadj.) Rs41.4-24.9 -166.3%  
Cash flow per share (Unadj.) Rs50.92.5 1,999.5%  
Dividends per share (Unadj.) Rs2.500-  
Dividend yield (eoy) %0.40-  
Book value per share (Unadj.) Rs199.4293.3 68.0%  
Shares outstanding (eoy) m585.8812.34 4,747.8%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x2.30.3 753.9%   
Avg P/E ratio x15.9-3.8 -422.3%  
P/CF ratio (eoy) x12.936.7 35.1%  
Price / Book Value ratio x3.30.3 1,032.9%  
Dividend payout %6.00-   
Avg Mkt Cap Rs m384,6301,154 33,336.2%   
No. of employees `00017.30.9 1,873.7%   
Total wages/salary Rs m21,308393 5,420.6%   
Avg. sales/employee Rs Th9,500.74,026.1 236.0%   
Avg. wages/employee Rs Th1,229.4425.0 289.3%   
Avg. net profit/employee Rs Th1,397.9-331.8 -421.3%   
INCOME DATA
Net Sales Rs m164,6663,724 4,421.6%  
Other income Rs m1,02023 4,532.4%   
Total revenues Rs m165,6863,747 4,422.3%   
Gross profit Rs m37,718395 9,553.6%  
Depreciation Rs m5,580338 1,649.3%   
Interest Rs m777354 219.4%   
Profit before tax Rs m32,380-275 -11,761.9%   
Minority Interest Rs m310-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m8,18332 25,894.6%   
Profit after tax Rs m24,229-307 -7,894.8%  
Gross profit margin %22.910.6 216.1%  
Effective tax rate %25.3-11.5 -220.2%   
Net profit margin %14.7-8.2 -178.5%  
BALANCE SHEET DATA
Current assets Rs m121,8782,638 4,620.7%   
Current liabilities Rs m86,8062,305 3,766.6%   
Net working cap to sales %21.38.9 238.2%  
Current ratio x1.41.1 122.7%  
Inventory Days Days130135 95.9%  
Debtors Days Days6846 147.6%  
Net fixed assets Rs m81,0374,871 1,663.7%   
Share capital Rs m586123 474.8%   
"Free" reserves Rs m116,2183,496 3,324.6%   
Net worth Rs m116,8043,619 3,227.4%   
Long term debt Rs m4,5121,374 328.3%   
Total assets Rs m211,0527,509 2,810.8%  
Interest coverage x42.70.2 19,133.5%   
Debt to equity ratio x00.4 10.2%  
Sales to assets ratio x0.80.5 157.3%   
Return on assets %11.80.6 1,876.9%  
Return on equity %20.7-8.5 -244.6%  
Return on capital %27.41.6 1,729.2%  
Exports to sales %00-   
Imports to sales %013.9 0.0%   
Exports (fob) Rs mNANA-   
Imports (cif) Rs mNA517 0.0%   
Fx inflow Rs m80,7270-   
Fx outflow Rs m34,700517 6,718.4%   
Net fx Rs m46,027-517 -8,911.3%   
CASH FLOW
From Operations Rs m19,548514 3,800.2%  
From Investments Rs m-19,570-123 15,897.2%  
From Financial Activity Rs m8,642-387 -2,232.4%  
Net Cashflow Rs m8,9224 212,431.0%  

Share Holding

Indian Promoters % 54.1 32.9 164.7%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 8.0 0.2 4,416.7%  
FIIs % 27.7 0.6 4,775.9%  
ADR/GDR % 0.0 0.0 -  
Free float % 10.2 66.4 15.4%  
Shareholders   69,601 20,121 345.9%  
Pledged promoter(s) holding % 8.6 36.4 23.5%  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare AUROBINDO PHARMA With:   CADILA HEALTHCARE  TTK HEALTHCARE  MERCK LTD  DISHMAN PHARMA  J.B.CHEMICALS  

Compare AUROBINDO PHARMA With:   ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  MYLAN (US)  TEVA PHARMA (Israel)  



Today's Market

From Urjit Patel to Shaktikanta Das; What Lies Ahead?(Podcast)

The week gone by saw Sensex plunge from 700 points to rise by over 600 points. With a volatile and eventful week, it was a challenge keeping up with the news every day.

Related Views on News

VENUS REMEDIES Announces Quarterly Results (2QFY19); Net Profit Down 16.3% (Quarterly Result Update)

Nov 23, 2018 | Updated on Nov 23, 2018

For the quarter ended September 2018, VENUS REMEDIES has posted a net profit of Rs 8 m (down 16.3% YoY). Sales on the other hand came in at Rs 809 m (down 10.6% YoY). Read on for a complete analysis of VENUS REMEDIES's quarterly results.

AUROBINDO PHARMA Announces Quarterly Results (2QFY19); Net Profit Down 21.6% (Quarterly Result Update)

Nov 14, 2018 | Updated on Nov 14, 2018

For the quarter ended September 2018, AUROBINDO PHARMA has posted a net profit of Rs 6 bn (down 21.6% YoY). Sales on the other hand came in at Rs 48 bn (up 7.1% YoY). Read on for a complete analysis of AUROBINDO PHARMA's quarterly results.

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

Lupin: US market Declines Due to Higher Base Effect of FY17 (Quarterly Results Update - Detailed)

Feb 9, 2018

Price erosion in generic US drugs continues but seems to be bottoming out.

More Views on News

Most Popular

4 Rebound Stocks to Profit from the Current Small Cap Crash(Profit Hunter)

Dec 3, 2018

Indian small cap space is offering a discount season. Make sure you do not get too late to scoop up the bargains.

It's Almost the Perfect Time to Buy This Safe Stock(The 5 Minute Wrapup)

Dec 6, 2018

My latest StockSelect recommendation ticks all the boxes of a great safe stock.

Looking For Higher Interest Rates on Bank FDs? Read This!(Outside View)

Dec 5, 2018

Credit disbursement to the productive sectors of the economy such as infrastructure, engineering, food processing, textiles, and chemicals, among others is rising.

Are Foreign Investors Heading Back to the Indian Stock Markets?(Chart Of The Day)

Dec 3, 2018

After months of heavy FII selling, November witnessed a return on foreign money into Indian equities...

DSP Mutual Fund's Sale of DHFL Bonds: Here's What You Need to Know(Outside View)

Dec 5, 2018

PersonalFN explains the probable reason as to why the capital market regulator has initiated DSP Mutual Fund's bond sale that caused DHFL stock to crash.

More

Small Investments
BIG Returns

Zero To Millions Guide 2019
Get our special report, Zero To Millions
(2019 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

AUROBINDO PHARMA SHARE PRICE


Dec 14, 2018 (Close)

TRACK AUROBINDO PHARMA

  • Track your investment in AUROBINDO PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON AUROBINDO PHARMA

AUROBINDO PHARMA - MERCK LTD COMPARISON

COMPARE AUROBINDO PHARMA WITH

MARKET STATS